MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) — CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s long-term growth plan. Jared Oasheim, who joined CVRx in 2015, was promoted from Vice President of Finance to Chief Financial Officer (CFO). He […]
Financial
Medicure Announces Settlement of Patent Infringement Action
WINNIPEG, MB, Nov. 18, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. (“Nexus”) in the U.S. District Court for the Northern District of Illinois, which […]
Quanterix Appoints William Geist as Chief Operating Officer
Geist brings operational experience to Quanterix as the company scales to support rapid growth and commercial success BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has named William Geist to the position of chief operating officer (COO), […]
Zynex Ranked 13th in Revenue Growth Among Medical Device Companies
ENGLEWOOD, Colo., Nov. 19, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced it has been ranked 13th in revenue growth among all medical device companies in the U.S. and Canada on Deloitte’s […]
Novoheart Holdings Inc. has Closed its Going-Private Transaction
VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu Ying Ngan Ng, Chi Wing Ngan […]
Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer
The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer BASKING RIDGE, N.J., Nov. 17, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that Dr. Douglas Losordo, […]
Itamar Medical Reports Record Third Quarter 2020 Revenues
Third Quarter Revenues Increase 36% to $11.0Million U.S. WatchPATTMRevenues Increase 55% to $8.9Million Full Year 2020 Revenue Guidance of $39.5 Million to $40.5 Million Company to Host Conference Call Today at 8:00am ET, 3:00pm IT CAESAREA, Israel, Nov. 17, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical […]
SANUWAVE Health Reports Third Quarter 2020 Financial Results
Transformational Acquisition Positions for Significant Growth in Fourth Quarter 2020 and Beyond SUWANEE, GA, Nov. 17, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, […]
Biotricity Reports Results for the Quarter Ended September 30, 2020
Revenues grow 64.8% over the immediately preceding quarter and a 115.3% increase over the corresponding period of the prior year Loss per share of 8.5 cents in line with levels of immediately preceding quarter REDWOOD CITY, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and […]
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary […]



